AnatomyDiseasesChemicals and DrugsAnalytical, Diagnostic and Therapeutic Techniques and EquipmentPhenomena and ProcessesInformation Science
Factor VIIIHemophilia Avon Willebrand Factorvon Willebrand DiseasesBlood Coagulation FactorsFactor XIIIPlasmaBlood Coagulation TestsBlood Coagulation Factor InhibitorsFactor IXFactor VIIBatroxobinThrombinBlood CoagulationFactor VFactor XIHemophilia BFactor XI DeficiencyFactor VIIaFactor VIIIaPartial Thromboplastin TimeBlood PlateletsFactor XaHexestrolFactor XFactor IXaHemostasisFibrinogenTransglutaminasesAntigensDansyl CompoundsThromboplastinFibrinFactor XIII DeficiencyFactor XIIAntithrombinsFactor VaCollagen Type VIIIAntibodiesIsoantibodiesHemarthrosisalpha-2-AntiplasminProthrombinKineticsMolecular Sequence DataBlood ProteinsMolecular WeightRistocetinPlasma CellsAmino Acid SequenceDeamino Arginine Vasopressin
AssayHemophiliaConcentratesFVIIIInhibitor2022Deficiency of FactorDeficient PlasmaAssaysWillebrand FactorPrevalenceInhibitorsAntihemophilic FactorELISASerumConcentrationsCryoprecipitateDDAVPAntibodiesPlatelets2020HemostasisProteinsTherapyDeficienciesProteinHaemophiliaPatientsThrombosisActivationDiagnosisHumanAlbuminClottingPlatelet-poor plasmaCascadeGeneVascularInfectiousGeneticChromosomeProteaseBloodLevelsViralSymptomaticMoleculeImmuneIntravenousCarrier
Assay9
  • The factor VIII assay is a blood test to measure the activity of factor VIII. (medlineplus.gov)
  • The vWF:Ag assay evaluates the total protein amount in plasma. (medscape.com)
  • 0.0001, 32% difference) in the post-Kogenate sample but not in the post-ReFacto AF (11% higher by chromogenic assay, ns) or post-Advate samples (3% lower by chromogenic, ns) when assays were calibrated with plasma standards. (whiterose.ac.uk)
  • It is confirmed by doing the factor assay. (pediatriconcall.com)
  • Additional tests include the VWF protein (VWF:Ag) assay, functional assay (VWF:RCo), the factor VIII assay and the platelet function assay. (renalandurologynews.com)
  • A recently published study evaluated the thermostability of murine retroviruses inocculated into factor concentrates, using a cell transformation assay (5). (cdc.gov)
  • In studies done at CDC, in cooperation with Cutter Laboratories, AIDS virus was added to factor VIII concentrate (virus titer 10((5))) and the factor was lyophilized and heated to 68 C (154.4 F). The residual virus titer was determined by an infectivity assay (6). (cdc.gov)
  • introduced two modifications to the traditional Bethesda assay (BA) for stabilization during the 2-hour incubation at 37°C: (i) buffering of normal pooled plasma (NPP) in the test and control mixtures with imidazole and (ii) substitution of FVIII-deficient plasma (FVIIIDP) for imidazole buffer (IB) in the control mixture and for specimen predilution. (cdc.gov)
  • Plasma from peripheral blood was collected to measure tumor necrosis factor-a (TNF-α) and interleukin-8 (IL-8) by ELISA and nitrite (NO3) using a Griess assay. (bvsalud.org)
Hemophilia27
  • was transmitted to individuals with hemophilia and frequent exposure to plasma-derived or recombinant clotting factors. (karger.com)
  • Methods: We used highly sensitive real-time PCR to test plasma samples from 127 consecutive individuals with hemophilia who consulted our hemophilia center either for treatment or for a standard. (karger.com)
  • Factor VIII is a medication used to treat and prevent bleeding in people with hemophilia A and other causes of low factor VIII. (wikipedia.org)
  • The cost of the clotting factors is 80% of all medical costs for people with hemophilia. (wikipedia.org)
  • Hemophilia A is an X-linked, recessive disorder caused by deficiency of functional plasma clotting factor VIII (FVIII), which may be inherited or arise from spontaneous mutation. (medscape.com)
  • The antihemophilic protein, Factor VIII, has been used to treat Hemophilia A patients, using either protein purified from pooled plasma or recombinant Factor VIII. (genengnews.com)
  • It is the deficiency of factor VIII or IX in the intrinsic pathway that causes hemophilia. (pediatriconcall.com)
  • Hemophilia is divided into severe, moderate, and mild diseases depending on the level of functional factor VIII or factor IX. (pediatriconcall.com)
  • There are two types of hemophilia - Hemophilia A and Hemophilia B. Hemophilia A results from deficiency or abnormality of factor VIII. (pediatriconcall.com)
  • Hemophilia B results from deficiency or abnormality of factor IX. (pediatriconcall.com)
  • Female carriers of hemophilia may be symptomatic due to lower than normal clotting factor levels. (pediatriconcall.com)
  • Factor VIII is the plasma protein that is functionally deficient in hemophilia A patients, resulting in the clinical bleeding disorder. (inknowvation.com)
  • [ 10 ] which, though significant, are not as severe as those seen in hemophilia A or hemophilia B . This finding reflects the important role factor XI plays in hemostasis. (medscape.com)
  • Hemophilia A and B are rare, genetic, X-linked deficiencies in the blood clotting factors VIII (FVIII) and IX (FIX), respectively. (globaldata.com)
  • However, cost constraints in the 8MM are expected to limit the premium pricing opportunities for new products such as late-to-market long-acting factor concentrates and new alternative coagulation promoters, thereby limiting the size of the hemophilia market. (globaldata.com)
  • Three patients are known to have had risk factors for AIDS other than hemophilia. (cdc.gov)
  • With the exception of one 31-year-old factor V-deficient individual with Kaposi's sarcoma (and without risk factors for AIDS other than his hemophilia), each patient had at least one opportunistic infection suggestive of an underlying cellular immune deficiency. (cdc.gov)
  • These nine persons had no risk factors for AIDS other than hemophilia. (cdc.gov)
  • In cooperation with numerous hemophilia treatment centers and physicians, CDC has studied over 200 recipients of factor VIII and 36 recipients of factor IX concentrates containing materials from U.S. donors. (cdc.gov)
  • The possibility of blood or blood products being vehicles for AIDS transmission to hemophilia patients has been supported by the finding of risk of acquisition of AIDS for intravenous drug abusers (7) and, subsequently, by reports of transfusion-associated AIDS cases (8). (cdc.gov)
  • While many U.S. hemophilia-associated AIDS patients have received blood products other than factor concentrates in the 5 years preceding their AIDS diagnosis, the occurrence of nine cases with no known risk factor or exposure other than the use of factor VIII preparations implicates these products as potential vehicles of AIDS transmission. (cdc.gov)
  • The advent of extended half‐life (EHL) recombinant clotting factors and innovative non‐factor replacement therapeutics, such as emicizumab, offers several advantages over existing products for the prophylactic treatment of people living with hemophilia (PwH). (uni-muenchen.de)
  • In the context of the recommended stepwise approach for laboratory diagnosis of hemophilia, we examine the diagnostic challenges associated with the use of EHL factors and novel non‐factor therapeutics and consider the optimal diagnostic approach in PwH who are receiving these treatments. (uni-muenchen.de)
  • Factor VIII assays are used to help replacement therapy in patients with hemophilia. (medscape.com)
  • [ 8 ] In a mouse model, isolated hepatocytes transplantation did not correct hemophilia A, but transplantation of a cellular fraction enriched in liver endothelial cells did. (medscape.com)
  • Hemophilia A is transmitted as a sex-linked recessive manner due to deficiency of factor VIII. (medscape.com)
  • Bleeding episodes in patients with hemophilia A can be managed by replacing factor VIII. (medscape.com)
Concentrates8
  • Factor 8 concentrates Do NOT work because they don't have enough vWf. (wikibooks.org)
  • Treating the bleeding episodes involves the prompt and proper use of clotting factor concentrates. (pharmiweb.com)
  • By the 1970s, coagulation factor concentrates made from human plasma were available, and by the 1980's we could guarantee that it was HIV free. (pattayamail.com)
  • Based on product type plasma fractionation market is classified into immunoglobulin, coagulation factor concentrates, albumin, and protease inhibitors amongst others. (clickpress.com)
  • In nine cases, factor VIII concentrates have been the only blood product reportedly used in the 5 years before diagnosis of AIDS. (cdc.gov)
  • The factor V-deficient patient with Kaposi's sarcoma had not used factor VIII concentrate products but had used large volumes of plasma and factor IX concentrates. (cdc.gov)
  • [ 5 ] Several commercial lyophilized factor VIII concentrates that use cryoprecipitate of pooled normal human plasmas are available. (medscape.com)
  • Because of the risk of transmission of viruses, factor VIII concentrates have been sterilized by heating in solution, by superheating to 80° C, and by exposure to organic solvent-detergents that inactivate lipid-enveloped viruses, including HIV, hepatitis B, and hepatitis C viruses. (medscape.com)
FVIII10
  • Technoclone Factor VIII INH Plasma, HCV Negative is an immune-adsorbed lyophilized normal human plasma with a specific inhibitor antibody added directed against FVIII activity (FVIII:C). It can be used as accuracy control of factor VIII inhibitor determination (Bethesda Test). (diapharma.com)
  • FVIII Inhibitor Plasma HCV neg. (diapharma.com)
  • Although the variability in factor VIII (FVIII):C measurement is well recognized, this has not been widely reported for post-FVIII infusion samples. (whiterose.ac.uk)
  • The most common subtype found in the general population is type-1 disease (approximately 90%) and is characterized by a simple decrease in the level of plasma FVIII: VWF antigen and activity. (renalandurologynews.com)
  • Usually there is a prolonged bleeding time, or a low plasma concentration of coagulation factor VIII (FVIII) or von Willebrand factor (vWF). (lu.se)
  • Desmopressin virtually immediately reduced bleeding time, enhanced platelet adhesiveness, and significantly increased plasma concentrations of FVIII and vWF. (lu.se)
  • The plasma concentrations of FVIII and vWF showed a significant increase after 4 months, whereas 7 months treatment with thyroxine was needed to reduce bleeding time significantly. (lu.se)
  • The proposed mechanism believed to underlie how ABO blood group may influence cardiovascular disease risk involves the possible regulatory effect of ABO antigens on plasma levels of von Willebrand factor (VWF) and coagulation factor VIII (FVIII) [ 18 , 19 ]. (hindawi.com)
  • While one‐stage and chromogenic assays have performed well with human‐derived FVIII and FIX and full‐length recombinant products, EHL recombinant factors are heterogeneous in structure and mode of action and therefore show wide variation in activity levels between different one‐stage assays, and between one‐stage and chromogenic assays. (uni-muenchen.de)
  • DESIGN AND METHODS: Plasma samples from the patient were studied after DDAVP or FVIII/VWF concentrate injections. (haematologica.org)
Inhibitor7
  • HAT and HAT RI address the three major challenges of current Factor VIII products for haemophilia A therapy, which are the short Factor VIII half-life, the intravenous application route and the high risk for inhibitor development. (pharmiweb.com)
  • HAT RI additionally provides modifications within the Factor VIII section to further reduce the risk of inhibitor development, one of the major issues in haemophilia A therapy. (pharmiweb.com)
  • Acquired factor V deficiency in a patient with a urinary tract infection presenting with haematuria followed by multiple haemorrhages with an extremely low level of factor V inhibitor: a case report and review of the literature. (medscape.com)
  • and one, factor VIII deficiency due to her postpartum acquisition of a factor VIII inhibitor. (cdc.gov)
  • Factor deficiency can be distinguished from factor inhibitor by an inhibitor screen. (medscape.com)
  • Positive controls were inhibitor-positive patient plasmas (George King Biomedical) diluted in FVIIIDP to approximately 1.0 NBU. (cdc.gov)
  • The effect of the NPP preparation used in the control mixture on its stability was evaluated using NPP (Precision Biologic) unbuffered and buffered with imidazole (Sigma-Aldrich) or with 4-(2-hydroxyethy l)-1-piperazineethanesulfonic acid (HEPES) (Acros Organics, Fairfield, NJ, USA) to pH 7.4 and mixed 1:1 with FVIIIDP, BSA or an inhibitor- negative patient plasma in duplicate. (cdc.gov)
20221
Deficiency of Factor2
Deficient Plasma1
Assays2
  • The two in indistinguishable clinically = they have to determined by specific factor assays. (wikibooks.org)
  • Centres calibrated assays with the local plasma standard and with ReFacto AF laboratory standard for the ReFacto AF sample. (whiterose.ac.uk)
Willebrand Factor7
Prevalence3
  • Rates of AIDS virus antibody prevalence were 74% for factor VIII recipients and 39% for factor IX recipients (3,4). (cdc.gov)
  • The prevalence of diabetes and overweight (one of the major risk factors for diabetes) continue to increase. (cdc.gov)
  • Information on the prevalence of diabetes disease, especially in its early stages, and associated risk factors will be used to help develop early intervention and prevention programs for the disabling consequences of this condition. (cdc.gov)
Inhibitors7
  • Testing for inhibitors is indicated when bleeding is not controlled after infusion of adequate amounts of factor concentrate during a bleeding episode. (medscape.com)
  • The presence of inhibitors is indicated by failure of correction of clotting times with 1:1 mix with normal plasma. (medscape.com)
  • Up to 30% of patients with severe haemophilia develop antibodies (inhibitors) against the therapeutic factor VIII. (pharmiweb.com)
  • Binding of factor XIa to activated platelets localizes it to the site of clot formation and protects it from plasma protease inhibitors. (medscape.com)
  • The active ingredient comprises plasma proteins such as albumin , immunoglobulins, other globulins, coagulation factors, complement proteins and protease inhibitors. (rxlist.com)
  • There is a significant unmet need for new therapies that can reduce the great treatment burden associated with intravenous administration, the frequency of prophylactic infusions, and the risk of developing neutralizing antibodies, or inhibitors, against replacement factors. (globaldata.com)
  • FFP is ineffective in managing bleeding due to direct factor Xa inhibitors. (msdmanuals.com)
Antihemophilic Factor1
  • Factor VIII (antihemophilic factor) is a key factor of the intrinsic clotting cascade. (medscape.com)
ELISA2
  • Methods: Plasma VWF, ADAMTS-13, angiopoietin-2 (Ang2), and syndecan-1 levels were determined by ELISA. (imperial.ac.uk)
  • Tumor necrosis factor-α (TNF-α), interleukin (IL)-1β, IL-6 and IL-8 concentrations were measured by ELISA in both bronchoalveolar lavage (BAL) fluid and serum. (karger.com)
Serum4
  • The panel has been validated for use with tissue culture supernatant, serum, and plasma samples. (biolegend.com)
  • Serum folate, vitamin B12, methylmalonic acid and plasma homocysteine were determined. (degruyter.com)
  • Diabetes mellitus will be assessed by measures of blood glycohemoglobin, plasma glucose, serum insulin, and serum c-peptide in participants aged 12 years and over. (cdc.gov)
  • Measures of blood glycohemoglobin, plasma glucose, serum insulin, and serum c-peptide in the morning examination session only can be found in the Lab10AM data file. (cdc.gov)
Concentrations5
  • On the other hand, a study by Georgi et al indicated that in persons genetically disposed to lower concentrations of factor XI, the risk of venous thrombosis and ischemic stroke are reduced. (medscape.com)
  • Another aim was to study the long-term effect of thyroxine replacement on the plasma concentrations of coagulation factors and to ascertain the duration of thyroxine treatment needed to restore haemostatic function. (lu.se)
  • one had prolonged bleeding time, and one had low plasma concentrations of vWF:Ag. (lu.se)
  • These include low annual bleeding rates with less frequent dosing, higher trough plasma concentrations, and a more convenient route of administration. (uni-muenchen.de)
  • 0.05), whereas CRP, TNF-α , IL-1β and IL-8 concentrations showed no difference between SIRS and non-SIRS. (karger.com)
Cryoprecipitate2
  • Note: Storage of whole blood at refrigerated temperatures prior to processing may lead to cryoprecipitate formation and falsely low Factor VIII. (rchsd.org)
  • Both of cryoprecipitate and fresh-frozen plasma (FFP) contain factor VIII and were the only products available for treatment in the past. (medscape.com)
DDAVP2
  • therefore, the majority of patients with VWD achieve a clinical and laboratory remission of the disease during pregnancy, and treatment with 1-deamino-8-D-arginine vasopressin (DDAVP) or blood transfusion is usually not necessary. (renalandurologynews.com)
  • RESULTS: After 1-deamino-8-D-argine vasopressin (DDAVP) infusion, factor VIII and VWF activities increased and HMW VWF multimers were transiently observed in the patient's plasma. (haematologica.org)
Antibodies2
Platelets6
  • whole blood after collection should not be stored at refrigerator temperatures (+2°C to +4°C) owing to cold-induced binding of vWF to platelets and selective loss of vWF:Ag in plasma. (medscape.com)
  • Important in the maintenance of hemostasis, it promotes adhesion of platelets to the sites of vascular injury by forming a molecular bridge between sub-endothelial collagen matrix and platelet-surface receptor complex GPIb-IX-V. Also acts as a chaperone for coagulation factor VIII, delivering it to the site of injury, stabilizing its heterodimeric structure and protecting it from premature clearance from plasma. (rcsb.org)
  • DIC starts as a procoagulant condition, but as platelets and coagulation factors are used up in micro- and macrothromboses, patients develop a hemorrhagic phenotype. (vin.com)
  • Because DIC is a consumptive process with regards to coagulation factors, most of the bedside diagnostics are focused on the demonstration of consumption of platelets and coagulation factors, or on the discovery of elevated products of fibrinolysis and clot breakdown (e.g. (vin.com)
  • Washed RBCs are free of almost all traces of plasma, most white blood cells, and platelets. (msdmanuals.com)
  • Fresh frozen plasma (FFP) is an unconcentrated source of all clotting factors without platelets. (msdmanuals.com)
20201
  • Biotest unveiled functional data from its new Factor VIII compounds at the ISTH 2020 congress (International Society on Thrombosis and Haemostasis). (pharmiweb.com)
Hemostasis4
Proteins3
  • Biotest is a provider of plasma proteins and biological drugs. (pharmiweb.com)
  • Advancement towards improved purity and isolation of unique, novel plasma proteins remain primary focal points amongst leading market participants in plasma fractionation market, besides leading institutes are keen on accentuating novel discovery in protein therapeutics such as plasmin, iga, and ceruloplasmin. (clickpress.com)
  • The content and distribution of plasma proteins in Octaplas are comparable to reference ranges for healthy blood donors, except for Protein S and alpha2-antiplasmin. (rxlist.com)
Therapy4
  • In the early 1990s, pharmaceutical companies began to produce recombinant synthesized factor products, which now prevent nearly all forms of disease transmission during replacement therapy. (wikipedia.org)
  • Treatment modalities for CSC include focal laser photocoagulation, photodynamic therapy (PDT), and intravitreal anti-vascular endothelial growth factor (VEGF) injections [ 14 ]. (plos.org)
  • The authors suggested that the risk of venous thrombosis and ischemic stroke may be significantly reduced by pharmacologic inhibition of factor XI, with no clear evidence demonstrating that this therapy would increase the risk for major bleeding. (medscape.com)
  • 4 In addition, vascular endothelial growth factor (VEGF) is an angiogenic factor that regulates endothelial survival, proliferation, differentiation, and vascular permeability, and has been shown to be an important candidate for cancer therapy as it is upregulated in many tumors. (beckman.com)
Deficiencies3
  • Ragni MV. Hemorrhagic disorders: coagulation factor deficiencies. (medlineplus.gov)
  • Significant advancement in protein therapeutics development targeted for critical medical conditions such as congenital deficiencies, immunological disorders, and infections leverages growth in plasma fractionation market. (clickpress.com)
  • The dosage of Octaplas for replacement of multiple coagulation factors in patients with acquired deficiencies is 10 to 15 milliliters per kg. (rxlist.com)
Protein6
  • In addition, vWF is a carrier protein for factor VIII and prevents its proteolytic degradation in plasma. (medscape.com)
  • von Willebrand protein is also a carrier protein for Factor 8 = if it is not working properly you have decreased factor 8 as well. (wikibooks.org)
  • When these mutations were incorporated into a cellular clone producing Factor VIII, the resultant protein still performed its role in the clotting cascade without raising an anti-Factor VIII immune response. (genengnews.com)
  • In the light of growing demands for protein based therapeutics, leading market participant in plasma fractionation spectrum, CSL Ltd. has recently confirmed its investment worth $ 170 million to augment superlative albumin production at a new facility. (clickpress.com)
  • The impor- objectives of determining the frequencies tance of FVII in normal haemostasis is il- of these gene polymorphisms in the popula- lustrated by the severe bleeding diathesis tion and clarifying the genotype association associated with low plasma levels of the of the R353Q and 0/10 bp insertion poly- protein [ 3 ]. (who.int)
  • Factor VIIIa is inactivated by thrombin or activated protein C (APC). (medscape.com)
Haemophilia4
  • HAT and HAT RI (Haemophilia A Therapeutic and Haemophilia A Therapeutic Reduced Immunogenicity) are in preclinical development for the treatment of haemophilia A. HAT and HAT RI are characterized by a substantial half-life extension of Factor VIII and the potential for intravenous and subcutaneous administration. (pharmiweb.com)
  • Haemophilia A is caused by a deficiency of clotting factor VIII. (pharmiweb.com)
  • Just to confuse the issue, we also call Christmas Disease by other names, including Factor IX deficiency, haemophilia II, haemophilia B, haemophiloid state C, hereditary plasma thromboplastin component deficiency, plasma thromboplastin component deficiency, and plasma thromboplastin factor-B deficiency. (pattayamail.com)
  • Once it became clear that haemophilia was caused by a deficiency of a coagulation factor, replacement of the missing factor became the method of treatment. (pattayamail.com)
Patients14
  • A study by Ladikou et al indicated that patients with coronavirus disease 2019 (COVID-19) commonly have high levels of vWF and factor VIIIc, which may play a role in the hypercoagulable state and increased venous thromboembolism (VTE) rate encountered in COVID-19. (medscape.com)
  • Delev D, Pavlova A, Heinz S, Seifried E, Oldenburg J. Factor 5 mutation profile in German patients with homozygous and heterozygous factor V deficiency. (medscape.com)
  • Girolami A, Scandellari R, Lombardi AM, Girolami B, Bortoletto E, Zanon E. Pregnancy and oral contraceptives in factor V deficiency: a study of 22 patients (five homozygotes and 17 heterozygotes) and review of the literature. (medscape.com)
  • A study by Kyrle et al reported that in patients who had experienced an unprovoked venous thromboembolism (VTE), the 10-year probability of VTE recurrence was 31% in individuals below the 34th percentile for factor XIa, compared with 43% for those between the 34th and 67th percentiles, and 41% for patients in a higher percentile. (medscape.com)
  • Moreover, the results indicated that among patients with lower factor XI levels, the absolute risk reductions are greater in individuals at high risk for thrombosis, including those with atrial fibrillation or cancer. (medscape.com)
  • and for plasma exchange in patients with thrombotic thrombocytopenic purpura ( TTP ). (rxlist.com)
  • The dosage of Octaplas for plasma exchange in patients with TTP is 1 to 1.5 plasma volumes (40 to60 milliliters per kg). (rxlist.com)
  • Patients can be treated either on-demand or prophylactically using plasma-derived or recombinant replacement factors, the current standard of care. (globaldata.com)
  • We evaluated plasma BDNF and associations with symptoms in 22 patients with TRD enrolled in a randomized controlled trial of ketamine compared to an anaesthetic control (midazolam). (nih.gov)
  • In many patients with a deficiency of VWF, low level of factor VIII has been found. (medscape.com)
  • They are generally given to patients who have severe reactions to plasma (eg, severe allergies, paroxysmal nocturnal hemoglobinuria, IgA immunization). (msdmanuals.com)
  • Les données ont été recueillies à partir des dossiers de 920 patients atteints de diabète, d'hypertension et d'hypercholestérolémie en consultation dans des hôpitaux, des cliniques et des laboratoires d'analyses de Bagdad, et de 200 témoins en bonne santé. (who.int)
  • Data analysis demonstrated that DS patients with PD present high levels of TNF-a and IL-8 when compared with DS patients without PD. (bvsalud.org)
  • According with these results, it was concluded that TNF-α and IL-8 are produced by DS patients with PD. (bvsalud.org)
Thrombosis1
  • Employing data related to genetic variants that alter factor XI levels, the investigators found that in these individuals, the odds ratios (ORs) for venous thrombosis and ischemic stroke were 0.1 and 0.47, respectively, with the OR for major bleeding being 0.7. (medscape.com)
Activation3
Diagnosis1
  • Chorionic villus biopsy at 8 weeks gestation on amniocentesis at 12-14 weeks can be used for prenatal diagnosis by DNA analysis if the mother's carrier state is demonstrated either by mutation analysis or Restriction Fragment Length polymorphism study. (pediatriconcall.com)
Human11
  • A purified factor VIII concentrate is made from human blood plasma. (wikipedia.org)
  • Biotest develops and markets immunoglobulins, coagulation factors and albumin based on human blood plasma. (pharmiweb.com)
  • Asp68His mutation in the A1 domain of human factor V causes impaired secretion and ineffective translocation. (medscape.com)
  • Presently, the commercial factor VIII product is purified from pooled blood plasma obtained from human donors. (inknowvation.com)
  • Binding in media from cultured human umbilical vein ECs s and in plasma was determined by immunoprecipitation experiments. (imperial.ac.uk)
  • 2009. Nattokinase decreases plasma levels of fibrinogen, factor VII, and factor VIII in human subjects. (kompava.sk)
  • Our Octaplas, Pooled Plasma (human), Solvent/Detergent Treated Solution for Intravenous Infusion Side Effects Drug Center provides a comprehensive view of available drug information on the potential side effects when taking this medication. (rxlist.com)
  • Octaplas is a sterile, pyrogen free, frozen solution of solvent/detergent (S/D) treated pooled human plasma. (rxlist.com)
  • Octaplas is manufactured from human plasma collected in US licensed plasma donation centers. (rxlist.com)
  • In addition, the manufacturing plasma pool may not contain a titer of human Parvovirus B19 DNA exceeding 10.0 IU per microliter and must have a negative result in a test for human Hepatitis E Virus (HEV) RNA by NAT PCR with a sensitivity of ≤ 2.5 log 10 IU/mL. (rxlist.com)
  • 1977. Inhibition of human plasma cholinesterase by ingested dichlorvos: effect of formulation vehicle. (cdc.gov)
Albumin1
  • These benefits are based on the fusion of special Factor VIII sequences with four albumin-binding peptides shielding the active substance from degradation. (pharmiweb.com)
Clotting3
  • If Factor VIII Activity, Clotting is >20, Factor VIII Activity, Chromogenic will be performed. (rchsd.org)
  • Owren P. Parahaemophilia: haemorrhagic diathesis due to absence of a previously unknown clotting factor. (medscape.com)
  • Whole blood can provide improved oxygen-carrying capacity, volume expansion, and replacement of clotting factors and was previously recommended for rapid massive blood loss. (msdmanuals.com)
Platelet-poor plasma2
  • Platelet Poor Plasma: Centrifuge light blue-top tube 15 minutes at approx. (rchsd.org)
  • Centrifuge a second time and transfer platelet-poor plasma into a new plastic vial. (rchsd.org)
Cascade2
  • Recently several reports have cleotide (designated as 0/10 bp) in the pro- focused on the association between the moter region of the gene at position -323 factor VII of the cascade coagulation and [ 13,14 ]. (who.int)
  • In health, the procoagulant and proinflammatory actions of coagulation are balanced by endogenous anticoagulant factors that limit the effects of the coagulation cascade and can be anti-inflammatory as well. (vin.com)
Gene9
  • Familial coagulation factor V deficiency caused by a novel 4 base pair insertion in the factor V gene: factor V Stanford. (medscape.com)
  • The gene for factor XI is located on chromosome 4. (medscape.com)
  • In mice, knockout of the gene for factor XI does not lead to death in utero. (medscape.com)
  • Which pipeline agents - replacement factors, alternative coagulation promoters and gene therapies - are the most promising and expected to launch in the 8MM? (globaldata.com)
  • ABSTRACT Factor VII gene polymorphisms may contribute to elevations in factor VII coagulant (FVIIc) levels that have been associated with cardiovascular risk. (who.int)
  • The Q353 allele of the factor VII gene polymorphism is associated with decreased factor VII and could be protective against cardiovascular disease. (who.int)
  • 10976 in exon 8 in the catalytic region of ing factors that may increase cardiovascu- the FVII gene and an insertion of a decanu- lar disease. (who.int)
  • We studied FVII gene poly- then activates factors IX and X leading to morphisms in healthy Tunisians with the the generation of thrombin [ 2 ]. (who.int)
  • The factor VIII gene is located on the X chromosome. (medscape.com)
Vascular1
  • Upon contact with tissue ferences in FVII activity levels and in geno- factor exposed by vascular injury, FVII is type frequencies depend on the ethnic cleaved to its two-chain active form, which groups [ 15 ]. (who.int)
Infectious2
  • After 48 hours at 68 C (154.4 F), viral titers dropped from 10((8)) to two infectious particles/ml. (cdc.gov)
  • Div of Host Factors, Center for Infectious Diseases, CDC. (cdc.gov)
Genetic1
  • Genetic factors levels vary significantly in the general pop- contribute significantly to the development ulation and are influenced by environmental of these diseases. (who.int)
Chromosome1
  • Both are inherited as a sex-linked recessive disorder as the genes responsible for factor VIII & IX are located on the X chromosome. (pediatriconcall.com)
Protease1
  • Factor XI is synthesized in the liver and megakaryocytes and is an 80-kd zymogen precursor of a serine protease. (medscape.com)
Blood6
  • This transfer of a plasma byproduct into the blood stream of a hemophiliac often led to the transmission of diseases such as HIV and hepatitis before purification methods were improved. (wikipedia.org)
  • Results from further animal models support a 4-fold extension of the half-life in blood circulation while maintaining the wild-type characteristics of activated Factor VIII with full in vivo functionality. (pharmiweb.com)
  • ABO blood group and body mass index (BMI) have individually been appraised as risk factors for certain diseases. (hindawi.com)
  • ECs control blood flow by initiating the vasodilation and vasoconstriction of underlying smooth muscle with the release of various vasoactive factors. (beckman.com)
  • Key market players and stakeholders are akin on investing thoroughly towards development of apt safety measures to reduce incidences of blood- borne maladies triggered by plasma fractionation. (clickpress.com)
  • Each lot of Octaplas is manufactured from pooled plasma of a single AB0 blood group (A, B, AB, or 0). (rxlist.com)
Levels6
  • Cloudy plasma may result in underestimation of vWF:Ag levels, while the presence of rheumatoid factor in the plasma can produce overestimation. (medscape.com)
  • Moderate hemophiliacs (factor levels - 2to5%) experience more bleeds, about once a month, usually after trauma, surgery, or extreme exertion. (pediatriconcall.com)
  • A study by Gill et al indicated that greater genetically determined levels of factor XI increase the risk of ischemic stroke arising from cardioembolisms, while not impacting ischemic stroke risk associated with large artery atherosclerosis or small artery occlusion. (medscape.com)
  • Ketamine significantly increased plasma BDNF levels in responders compared to non-responders 240 min post-infusion, and Montgomery-Åsberg Depression Rating Scale (MADRS) scores were negatively correlated with BDNF (r=-0.701, p = 0.008). (nih.gov)
  • Plasma BDNF levels at 240 min post-infusion were highly negatively associated with MADRS scores at 240 min (r = -0.897, p=.002), 24 h (r = -0.791, p = 0.038), 48 h (r = -0.944, p = 0.001) and 72 h (r = -0.977, p = 0.010). (nih.gov)
  • A large volume of plasma must be infused to achieve and maintain even lowest factor VIII levels. (medscape.com)
Viral1
  • All plasma donations are tested for viral markers in compliance with US regulation. (rxlist.com)
Symptomatic1
  • You can be a symptomatic or asymptomatic carrier depending on other factors. (wikibooks.org)
Molecule2
  • By comparing responses to different amino acid sequences, a T-cell epitope map can be built up which allows the scientist to predict what modification can be designed into the Factor VIII molecule to make it less immunogenic. (genengnews.com)
  • Recent experiments have indicated that the Factor VIII molecule can be extensively modified by techniques of molecular genetics and retain its in vitro and in vivo activity. (inknowvation.com)
Immune1
  • We used high-throughput B cell receptor sequencing of plasma cells produced following AS03-adjuvanted and non-adjuvanted 2009 pandemic H1N1 vaccination, as well as pre-pandemic seasonal influenza vaccination to elucidate the effect of the adjuvant on the humoral immune response. (nature.com)
Intravenous2
  • Factor VIII is delivered by intravenous infusion. (wikipedia.org)
  • 1 g (1 ampoule of 10 ml or 2 ampoules of 5 ml) tranexamic acid by slow intravenous injection (= 1 ml/minute) every 6 to 8 hours, equivalent to 15 mg/kg BW. (medicines.org.uk)
Carrier1